Abstract
Age associated neurodegenerative diseases are characterized by intra- and extracellular aggregation and deposition of misfolded proteins. The neuropathological classification of neurodegenerative diseases is based on the semiquantitative assessment of these misfolded proteins, that constitute the neuropathological hallmark lesion for the respective disease: e.g. Alzheimer's disease (AD), amyloid-β (Aβ) hyperphosphorylated tau (tau); Lewy body diseases, α- synuclein (α-syn); frontotemporal lobar degeneration, tau, TDP-43, ubiquitin or FUS. In addition, cerebovascular lesions are assessed for the diagnosis of vascular dementia. However, in brains of elderly patients suffering from neurodegenerative diseases multiple pathologies are usually present and even in clinically characterized prospective cohorts additional pathologies are frequently found at post mortem examination. On the other hand, various amounts of AD pathology are frequently seen in brains of non-demented elderly and the threshold to cause clinical overt dementia is ill defined as additional co-morbidities (e.g., cerebrovascular lesions) might lower the threshold for clinical dementia in some cases. It becomes increasingly clear that the clinical picture of dementia in most aged patients results from a multimorbid condition in the CNS rather than from one single disease and data from animal studies suggest that Aβ, tau, and α-syn interact in vivo to promote the aggregation and accumulation of each other. We suggest that clinico-pathologocal correlative studies using a more quantitative approach in the assessment of neuropathological lesions are warranted to elucidate cerebral multimorbidity and to identify suitable targets for targeted therapeutic strategies against age associated neurodegeneration.
Keywords: Alzheimer's disease, lewy body diseases, amyloid-β, α-synuclein, hyperphosphorylated tau, TDP-43.
Current Alzheimer Research
Title:Neuropathological Correlates of Cerebral Multimorbidity
Volume: 10 Issue: 6
Author(s): Johannes Attems and Kurt Jellinger
Affiliation:
Keywords: Alzheimer's disease, lewy body diseases, amyloid-β, α-synuclein, hyperphosphorylated tau, TDP-43.
Abstract: Age associated neurodegenerative diseases are characterized by intra- and extracellular aggregation and deposition of misfolded proteins. The neuropathological classification of neurodegenerative diseases is based on the semiquantitative assessment of these misfolded proteins, that constitute the neuropathological hallmark lesion for the respective disease: e.g. Alzheimer's disease (AD), amyloid-β (Aβ) hyperphosphorylated tau (tau); Lewy body diseases, α- synuclein (α-syn); frontotemporal lobar degeneration, tau, TDP-43, ubiquitin or FUS. In addition, cerebovascular lesions are assessed for the diagnosis of vascular dementia. However, in brains of elderly patients suffering from neurodegenerative diseases multiple pathologies are usually present and even in clinically characterized prospective cohorts additional pathologies are frequently found at post mortem examination. On the other hand, various amounts of AD pathology are frequently seen in brains of non-demented elderly and the threshold to cause clinical overt dementia is ill defined as additional co-morbidities (e.g., cerebrovascular lesions) might lower the threshold for clinical dementia in some cases. It becomes increasingly clear that the clinical picture of dementia in most aged patients results from a multimorbid condition in the CNS rather than from one single disease and data from animal studies suggest that Aβ, tau, and α-syn interact in vivo to promote the aggregation and accumulation of each other. We suggest that clinico-pathologocal correlative studies using a more quantitative approach in the assessment of neuropathological lesions are warranted to elucidate cerebral multimorbidity and to identify suitable targets for targeted therapeutic strategies against age associated neurodegeneration.
Export Options
About this article
Cite this article as:
Attems Johannes and Jellinger Kurt, Neuropathological Correlates of Cerebral Multimorbidity, Current Alzheimer Research 2013; 10 (6) . https://dx.doi.org/10.2174/15672050113109990002
DOI https://dx.doi.org/10.2174/15672050113109990002 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design of Some New Potent Beta-secretase Inhibitors Based on QSAR and Molecular Modeling Study on a Series of Hydroxyethylamine Derivatives
Letters in Drug Design & Discovery Diagnosis, Pathogenesis and Therapeutic Targets in Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets Caspase-3 Short Hairpin RNAs: A Potential Therapeutic Agent in Neurodegeneration of Aluminum-Exposed Animal Model
Current Alzheimer Research Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Aquaporin and Vascular Diseases
Current Neuropharmacology Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design Attentional Set-Shifting in Rodents: A Review of Behavioural Methods and Pharmacological Results
Current Pharmaceutical Design AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer’s Disease
Current Neuropharmacology Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Primary and Secondary Stroke Prevention with Antiplatelet Drugs
Current Pharmaceutical Design Preventing the Spread of Alzheimer’s Disease Neuropathology: A Role for Calcilytics?
Current Pharmaceutical Biotechnology Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinsons Disease: Potential Implications in Cognitive Dysfunction and Dementia?
Current Medicinal Chemistry Soothing the Inflamed Brain: Effect of Non-Steroidal Anti-Inflammatory Drugs on Alzheimers Disease Pathology
CNS & Neurological Disorders - Drug Targets Health-Care Associated Pneumonia (HCAP): Identification of Low and High-Risk Patients
Current Respiratory Medicine Reviews Conference Report [IANR V and 9th GCNN Conference with 4th ISCITT Symposium]
CNS & Neurological Disorders - Drug Targets Donepezil Base: Physicochemical Characterization, HPLC Method Development, Validation and its Application for the Determination of Shelf Life in Developed Solid Lipid Nanoparticles
Current Nanomedicine Physical Inactivity is Liable to the Increased Cardiovascular Risk and Impaired Cognitive Profile
Current Alzheimer Research Oleanolic Acid Ameliorates Aβ25-35 Injection-induced Memory Deficit in Alzheimer’s Disease Model Rats by Maintaining Synaptic Plasticity
CNS & Neurological Disorders - Drug Targets Targeting NO/cGMP Signaling in the CNS for Neurodegeneration and Alzheimer’s Disease
Current Medicinal Chemistry